Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
Nina Shah, MD, discusses maintenance therapies in emerging clinical trials for multiple myeloma.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: Clinical trials are the cornerstone for all of the progress that we’ve had in multiple myeloma, and I’m so thankful to all the investigators and particularly the patients and their families that have participated. Some of the trials I’m really excited about are the maintenance trials, including the SWOG DRAMMATIC trial [NCT04071457], which randomizes patients to get lenalidomide [Revlimid] versus daratumumab [Darzalex] plus lenalidomide with a very interesting subsequent pattern where if patients are MRD negative, they’re randomized to stop therapy or not depending on whichever arm they’re in. Then there’s the AURIGA trial [NCT03901963] that is also randomizing patients to lenalidomide versus daratumumab plus lenalidomide, and the primary end point there is increase or achievement of MRD negativity status at 1-year post treatment. That’s going to be important as far as trying to understand end points that are [achieved] earlier, but are very predictive and are also using combination maintenance therapy. Other trials that are critical are the immunotherapy trials that are combining things like, for example teclistamab and talquetamab [JNJ-64407564] or having these things in the earlier lines of treatment. Patients can do better with these effective therapies if they get them earlier and not in the late line when they have exhausted immune systems.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
